AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 291 min read$INSM

Insmed 3Q 2026: Revenue $524.4M, Net loss $100.3M, EPS $(0.46) — 10-Q Summary

Insmed reported 3Q 2026 revenue of $524.4M, up 268% YoY, driven by BRINSUPRI sales. Net loss was $100.3M, or $(0.46) per share, improving from $(1.75) YoY. BRINSUPRI sales reached $398.1M in the U.S., and the drug was launched in Japan. ARIKAYCE revenue grew 9%, with an FDA priority review for label expansion. Phase 3 studies for TPIP are ongoing, with a new IPF study planned for 1H 2027.

Original reporting
tradingview.com
Published Oct 29, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Insmed 3Q 2026: Revenue $524.4M, Net loss $100.3M, EPS $(0.46) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$INSMBullishHigh
01

Why it matters

The earnings release provides fresh, material information that could trigger a price move, especially given the magnitude of revenue growth and loss improvement.

02

Market read

Primary earnings disclosure for a listed biotech; high relevance for traders tracking earnings catalysts.

03

What to watch

Future FDA priority review for ARIKAYCE label expansion and upcoming Phase 3 studies could add risk if trials miss milestones.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Insmed Inc (NASDAQ: INSM) filed its Form 10‑Q for Q3 2026, reporting a dramatic revenue surge driven by its BRINSUPRI product and a narrowing net loss.

Company-level read

Ticker impact

$INSMBullishHigh confidence
Context

Q3 2026 earnings released with revenue up 268% YoY to $524.4M and net loss narrowing to $100.3M.

Expected impact

likely upward pressure as market prices in strong revenue growth and narrowing losses

Evidence & confidence

First report of the quarter's results; material revenue increase and loss reduction are fresh data that can move the price.

Market effects

Sector

Biotech sector may see renewed interest in rare‑disease therapies after positive sales of BRINSUPRI and ARIKAYCE.

Regional

U.S. biotech investors likely to react; Japan market may see modest uplift from drug launch.

Global

Limited to biotech investors; not a broad market driver.

Counterpoint

What could challenge this read

Losses remain sizable; investors may stay cautious until profitability is demonstrated.

Key entities

  • company
    Insmed Inc

    Biopharmaceutical company focused on rare pulmonary diseases.

Read at source← All news

StoryInsmed raises 2026 revenue guidance after strong third-quarter results

Also covered by

4 outlets

Related articles

OCT 30
$INSMHighAI 8/10

Why Did Insmed Stock Jump?

Insmed (INSM) shares rose 15.1% on October 29, 2026, after reporting Q3 2026 results. Revenue of $524.4M beat estimates, but loss per share was wider. BRINSUPRI revenue grew 29% QoQ, and guidance was raised. R&D and sales costs increased 40% YoY. The stock is down 32.5% over the past year.

finance.yahoo.com2 min
OCT 30
$INSMHighAI 9/10

Goldman Sachs reiterates Insmed stock rating on Brinsupri beat

Goldman Sachs maintained a Buy rating and $194 price target for Insmed (INSM) after its quarterly results beat estimates. Brinsupri revenue was $400.1M, exceeding expectations. Insmed raised its 2026 guidance for Brinsupri to $1.35B-$1.40B. The stock rose 19.5% to $111.59. Analysts have revised earnings upwards, with price targets ranging from $165 to $243.

investing.com2 min
OCT 29
$INSMMed

Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status

Insmed Inc (INSM) reported positive Q3 2026 earnings, with Brinsupri showing strong persistency and revenue trends. The company expects cash flow positivity in 2027 and provided updates on TPIP trials and Erakase's label expansion. Dr. Martina Flammer highlighted growth opportunities in comorbid COPD and asthma bronchiectasis, with data expected in mid-2027. Insmed also discussed AI use for patient identification and the potential impact of real-world studies.

finance.yahoo.com2 min
OCT 29
$INSMMedAI 8/10

What Insmed (INSM) Said on Its Q3 Earnings Call

Insmed (INSM) reported Q3 earnings, highlighting AI diagnostic tools for bronchiectasis, expected to share findings in 2027. FDA granted priority review for ARIKAYCE's sNDA, with a target action date of Jan. 28, 2027. The company expects cash-flow positivity in 2027. Insmed also provided updates on its pipeline, including TPIP and INS1033 programs. Cost of product revenues was $78.2 million, or 14.9% of revenue, with combined R&D and SG&A expenses up 40% year over year.

finance.yahoo.com2 min
OCT 29
$INSMHighAI 8/10

Insmed (INSM) Q3 2026 Earnings Call Transcript

Insmed (INSM) reported Q3 2026 revenue of $400.1M for BRINSUPRI, up 29% sequentially. The company raised its 2026 revenue guidance to $1.35B-$1.4B. Insmed expects its lead respiratory assets to exceed $14B in peak sales, with BRINSUPRI potentially reaching $7B+ and TPIP $6B+.

finance.yahoo.com3 min